QuidelOrtho partially recovers from earnings slide, rising 12% (QDEL:NASDAQ)
QuidelOrtho (QDEL) stock rebounds 12% after Q2 earnings beat but sharp 2026 guidance cut.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
QuidelOrtho (QDEL) stock rebounds 12% after Q2 earnings beat but sharp 2026 guidance cut.
QuidelOrtho partially recovers from earnings slide, rising 12% (QDEL:NASDAQ) | Seeking Alpha
Adam Smigielski/E+ via Getty Images
QuidelOrtho (
QDEL
) shares rose just under 12% on Monday, rebounding after a brutal two-session decline spurred by the diagnostics company's Q2 earnings release. The stock finished at $13.75, rising $1.46 on the day.
The bounce came after QDEL shed almost
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Quick Insights
Why did QuidelOrtho shares decline sharply after Q2 earnings?
Despite beating top and bottom line estimates, QuidelOrtho issued significant cuts to full-year revenue and EPS guidance and withdrew free cash flow guidance, raising investor concerns over future growth and profitability.
What are the primary risks impacting QuidelOrtho's future outlook?
Major risks include reduced demand in China due to proposed IVD pricing guidelines and a softer global respiratory environment, directly impacting revenue and management's ability to provide guidance.
How are analysts and investors reacting to QuidelOrtho's recent performance and outlook?
Analysts cite the potential benefit of asset sales to reduce leverage and improve valuation, but short interest remains high over concerns of continuing losses. Investor sentiment is frustrated but some are maintaining positions, hoping for a turnaround.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Anaergia reports Q2 results (TSX:ANRG:CA)
Anaergia press release (ANRG:CA): Q2 Revenue of C$63.9M (+97.8% Y/Y). Adjusted EBITDA improved to positive C$1.9 million, compared with an Adjusted EBITDA loss
Bowman Consulting Non-GAAP EPS of $0.62 beats by $0.16, revenue of $146.12M beats by $0.32M (NASDAQ:BWMN)
Bowman Consulting press release (BWMN): Q2 Non-GAAP EPS of $0.62 beats by $0.16. Revenue of $146.12M (+19.7% Y/Y) beats by $0.32M. Full Year 2026 Guidance Bowma
Oruka Therapeutics GAAP EPS of -$0.55 misses by $0.01 (NASDAQ:ORKA)
Oruka Therapeutics press release (ORKA): Q2 GAAP EPS of -$0.55 misses by $0.01. As of June 30, 2026, Oruka had cash, cash equivalents and marketable securities
Powerfleet Raises FY2027 Guidance: South Africa Contract Drives Annualized Revenue to $495M with 27% EBITDA Margin
Powerfleet projects FY2027 Q4 annualized revenue of $495 million and adjusted EBITDA margin of 27%, driven by a major South Africa contract. The guidance upgrade signals strong growth and market confidence.
